Yung-Jue Bang
庞荣在
MD, PhD
Professor Emeritus of Internal Medicine; Former Director, Cancer Research Institute, Seoul National University内科荣誉教授，前首尔国立大学癌症研究所所长
👥Biography 个人简介
Yung-Jue Bang, MD, PhD is Professor Emeritus of Internal Medicine and former Director of the Cancer Research Institute at Seoul National University College of Medicine. He is among the most distinguished oncology researchers in Asia and a towering figure in the history of gastric cancer drug development. Dr. Bang is best known globally as the principal investigator of the ToGA (Trastuzumab for Gastric Cancer) trial—the pivotal phase III study that established trastuzumab plus cisplatin/fluorouracil as the first approved targeted therapy for HER2-positive advanced gastric and GEJ adenocarcinoma, with an overall survival benefit of 13.8 versus 11.1 months. ToGA transformed gastric cancer care worldwide and introduced the paradigm of biomarker-directed therapy to the field. Dr. Bang has subsequently led over 60 phase I–III trials in gastric and other GI cancers, including evaluations of lapatinib, checkpoint inhibitors, novel ADCs, and PI3K pathway inhibitors. He is a pioneer in first-in-human clinical trial conduct for GI malignancies in Asia and has contributed to the development of numerous approved agents. He has published over 800 papers and mentored generations of Korean and international oncologists.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ToGA — Establishing Trastuzumab as First Targeted Therapy in HER2+ Gastric Cancer
Led the ToGA phase III trial demonstrating that the addition of trastuzumab to cisplatin plus fluorouracil/capecitabine significantly improved overall survival (13.8 vs 11.1 months) in HER2-positive advanced gastric and GEJ adenocarcinoma, establishing trastuzumab as the first approved targeted therapy in gastric cancer and introducing biomarker-directed treatment to the field.
HER2 Testing and Scoring in Gastric Cancer
Led extensive studies defining HER2 testing methodology specific to gastric cancer, establishing that HER2 IHC/FISH scoring criteria developed for breast cancer required modification for the distinct pattern of HER2 overexpression in gastric tumors, developing the gastric-specific HER2 scoring system adopted by pathology guidelines worldwide.
Lapatinib and Second-Generation HER2 Inhibition in Gastric Cancer
Led the LOGiC trial evaluating lapatinib plus chemotherapy in first-line HER2-positive gastric cancer and contributed to understanding why lapatinib failed in this setting, providing mechanistic insights into differences between gastric and breast cancer HER2 dependence and informing subsequent ADC and bispecific antibody development.
Checkpoint Immunotherapy Development in Asian Gastric Cancer
Participated as a senior investigator in pivotal checkpoint inhibitor trials in Asian gastric cancer populations (KEYNOTE-059, KEYNOTE-061, CheckMate 649), characterizing how Asian gastric cancer molecular features influence immunotherapy response and shaping regional treatment guidelines.
Representative Works 代表性著作
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)
The Lancet (2010)
Landmark ToGA phase III trial establishing trastuzumab as the first approved targeted therapy in HER2-positive advanced gastric/GEJ cancer, with significantly improved overall survival.
HER2 evaluation in HER2-positive gastric or gastro-oesophageal junction cancer: Implications for the design of the ToGA trial
Annals of Oncology (2010)
Comprehensive analysis of HER2 testing methodology, concordance of IHC and FISH, and gastric-specific HER2 scoring system used in ToGA and subsequently adopted internationally.
Pembrolizumab as second-line therapy for advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-059)
The Lancet Oncology (2017)
Multicohort KEYNOTE-059 study demonstrating pembrolizumab activity in second-line and later gastric cancer, particularly in PD-L1-positive and MSI-H disease.
A randomised, multicentre, double-blind, placebo-controlled study of lapatinib as a component of trastuzumab/capecitabine/oxaliplatin-based combination therapy in patients with HER2-positive metastatic gastric/gastro-oesophageal junction cancer (TRIO-013/LOGiC)
Annals of Oncology (2015)
Negative LOGiC phase III trial of lapatinib in HER2-positive advanced gastric cancer, providing critical insights into HER2 dependence differences between gastric and breast cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 庞荣在 的研究动态
Follow Yung-Jue Bang's research updates
留下邮箱，当我们发布与 Yung-Jue Bang（Seoul National University College of Medicine / Seoul National University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment